Surgical Debulking Modifies Notch Signaling and May Improve Vismodegib Effectiveness for Locally Advanced Basal Cell Carcinoma
Smoothened inhibitors, such as vismodegib, exhibit remarkable success in treating patients with locally advanced basal cell carcinoma (LaBCC). Yet, vismodegib efficacy is hindered by notable side effects, which often lead to treatment discontinuation and subsequent relapse in patients with LaBCC. Pr...
Saved in:
Main Authors: | Natella Maglakelidze (Author), Samantha L. Gettle (Author), Amy L. Longenecker (Author), Allison T. Vidimos (Author), Elizabeth M. Billingsley (Author), Ryan P. Hobbs (Author), Charlene Lam (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Investigational agents in metastatic basal cell carcinoma: focus on vismodegib
by: Batty N, et al.
Published: (2012) -
Basal cell carcinoma: multimodal treatment and the role of neoadjuvant vismodegib
by: Pedro Carvalho Martins, et al.
Published: (2019) -
Granulation tissue masquerading as basal cell carcinoma after treatment with vismodegib
by: Jayson Miedema, MD, et al.
Published: (2018) -
Vismodegib: A smoothened inhibitor for the treatment of advanced basal cell carcinoma
by: Suruchi Aditya, et al.
Published: (2013) -
Characterization of intractable diarrhea resulting from vismodegib treatment for basal cell nevus syndrome
by: Ashmi Patel, MS, et al.
Published: (2023)